Peter Attia· MD
Recent paper by Josh Rabinowitz et al makes clear case it is not passing the liver to get into other cells.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Recent paper by Josh Rabinowitz et al makes clear case it is not passing the liver to get into other cells.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the study didn't find that much NR made it out of the liver in fact what the study if I recall and I know it's been so long since I look at it but I think that they saw na M nicotinamide was up in the blood but not nicotinamide rai beside which you presumably will still wanted some of that leaving the liver to go to get into other cells
there was a paper that came out from Princeton Josh Rabinowitz his lab that looked Aurel nicotinamide ride beside it was a tracer study that looked at mice where they gave them oral and are and basically the question was what is the fate of this where is it going and what that paper showed was the liver took because this was oral of course so that stuff gets the NR gets absorbed out of the gut presumably and very quickly everything in the gut makes its way to the liver first hence it's called this first pass effect and it was in the liver that most of that nr got turned into nad